



## CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

May 11, 2026

-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented-

-Visit CG Oncology at booth #3051-

DALLAS, May 11, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced its participation in the American Urological Association (AUA) 2026 Annual Meeting, taking place May 15–18, 2026, in Washington, D.C. CG Oncology will present first results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients and will be exhibiting at booth #3051. The AUA Annual Meeting is the largest global gathering of urologists and urologic professionals, showcasing the latest advances in urologic medicine, clinical research and patient care.

### First Results from CORE-008 Cohort CX

**Title:** *Phase 2 Study of Intravesical Cretostimogene Gnenadenorepvec with Gemcitabine in Patients with High-Risk BCG-Exposed or BCG-Unresponsive Non-Muscle Invasive Bladder Cancer*

- [Poster Presentation](#) May 15, 2026, 3:30 – 5:30 PM ET
- [Podium Presentation at the SUO 2026 Annual Meeting at the AUA](#) May 16, 2026, 4:25–4:30 PM ET

Additionally, the grant recipients of the annual **CG-SUO-CTC NMIBC Research Fellowship** will present their research at the SUO 2026 Annual Meeting at the AUA. This Fellowship is designed to support the development of outstanding clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). Details of the presentations are below:

- **Grant Recipient Taylor A. Goodstein, MD Presents: Spatial Transcriptomic Profiling of the Tumor Microenvironment in BCG-Unresponsive NMIBC Patients Treated with Novel Intravesical Gene Therapies**  
May 16, 4:45 PM-4:50 PM ET
- **Grant Recipient Saum B. Ghodoussipour, MD Presents : Dynamic intra-tumor heterogeneity in non-muscle invasive bladder cancer**  
May 16, 4:50 PM-4:55 PM ET

Attendees of AUA 2026 are encouraged to visit CG Oncology at booth #3051 to learn more about the company's clinical development program and its commitment to advancing innovative therapies for patients with bladder cancer.

### About CG Oncology

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: [www.cgoncology.com](http://www.cgoncology.com).

### Contacts

Media

Sarah Connors

Vice President, Communications and Patient Advocacy, CG Oncology

[sarah.connors@cgoncology.com](mailto:sarah.connors@cgoncology.com)

Investor Relations

Megan Knight

Vice President, Investor Relations, CG Oncology

[megan.knight@cgoncology.com](mailto:megan.knight@cgoncology.com)